Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-11-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-021-00551-y |
| _version_ | 1798033205935210496 |
|---|---|
| author | Jean Galtier Camille Alric Emilie Bérard Thibaut Leguay Suzanne Tavitian Audrey Bidet Eric Delabesse Jean Baptiste Rieu Jean-Philippe Vial François Vergez Nicolas Lechevalier Isabelle Luquet Emilie Klein Anne-Charlotte de Grande Audrey Sarry Arnaud Pigneux Christian Récher Sarah Bertoli Pierre-Yves Dumas |
| author_facet | Jean Galtier Camille Alric Emilie Bérard Thibaut Leguay Suzanne Tavitian Audrey Bidet Eric Delabesse Jean Baptiste Rieu Jean-Philippe Vial François Vergez Nicolas Lechevalier Isabelle Luquet Emilie Klein Anne-Charlotte de Grande Audrey Sarry Arnaud Pigneux Christian Récher Sarah Bertoli Pierre-Yves Dumas |
| author_sort | Jean Galtier |
| collection | DOAJ |
| first_indexed | 2024-04-11T20:25:30Z |
| format | Article |
| id | doaj.art-f96185a801b446e9a88718b9b046da3a |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-04-11T20:25:30Z |
| publishDate | 2021-11-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-f96185a801b446e9a88718b9b046da3a2022-12-22T04:04:40ZengNature Publishing GroupBlood Cancer Journal2044-53852021-11-0111111410.1038/s41408-021-00551-yIntermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomesJean Galtier0Camille Alric1Emilie Bérard2Thibaut Leguay3Suzanne Tavitian4Audrey Bidet5Eric Delabesse6Jean Baptiste Rieu7Jean-Philippe Vial8François Vergez9Nicolas Lechevalier10Isabelle Luquet11Emilie Klein12Anne-Charlotte de Grande13Audrey Sarry14Arnaud Pigneux15Christian Récher16Sarah Bertoli17Pierre-Yves Dumas18CHU Bordeaux, Service d’Hématologie Clinique et de Thérapie CellulaireService d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleService d’Epidémiologie, Centre Hospitalier Universitaire de ToulouseCHU Bordeaux, Service d’Hématologie Clinique et de Thérapie CellulaireService d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleCHU Bordeaux, Laboratoire d’Hématologie BiologiqueLaboratoire d’Hématologie Biologique, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleLaboratoire d’Hématologie Biologique, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleCHU Bordeaux, Laboratoire d’Hématologie BiologiqueLaboratoire d’Hématologie Biologique, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleCHU Bordeaux, Laboratoire d’Hématologie BiologiqueLaboratoire d’Hématologie Biologique, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleCHU Bordeaux, Laboratoire d’Hématologie BiologiqueCHU Bordeaux, Service d’Hématologie Clinique et de Thérapie CellulaireService d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleCHU Bordeaux, Service d’Hématologie Clinique et de Thérapie CellulaireService d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleService d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse OncopoleCHU Bordeaux, Service d’Hématologie Clinique et de Thérapie Cellulairehttps://doi.org/10.1038/s41408-021-00551-y |
| spellingShingle | Jean Galtier Camille Alric Emilie Bérard Thibaut Leguay Suzanne Tavitian Audrey Bidet Eric Delabesse Jean Baptiste Rieu Jean-Philippe Vial François Vergez Nicolas Lechevalier Isabelle Luquet Emilie Klein Anne-Charlotte de Grande Audrey Sarry Arnaud Pigneux Christian Récher Sarah Bertoli Pierre-Yves Dumas Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes Blood Cancer Journal |
| title | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_full | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_fullStr | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_full_unstemmed | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_short | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes |
| title_sort | intermediate dose cytarabine or standard dose cytarabine plus single dose anthracycline as post remission therapy in older patients with acute myeloid leukemia impact on health care resource consumption and outcomes |
| url | https://doi.org/10.1038/s41408-021-00551-y |
| work_keys_str_mv | AT jeangaltier intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT camillealric intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT emilieberard intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT thibautleguay intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT suzannetavitian intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT audreybidet intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT ericdelabesse intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT jeanbaptisterieu intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT jeanphilippevial intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT francoisvergez intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT nicolaslechevalier intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT isabelleluquet intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT emilieklein intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT annecharlottedegrande intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT audreysarry intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT arnaudpigneux intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT christianrecher intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT sarahbertoli intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes AT pierreyvesdumas intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes |